首页> Archives of disease in childhood> Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12-15 years.

Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12-15 years.

导出原文传递

翻译打印收藏纠错

第一作者： Hayley,King

第一单位： Department of Paediatric Immunology and Infectious Diseases, Bristol Royal Hospital for Children, Bristol, UK.

作者： Hayley,King ^[1] ; Sanjay,Deshpande ^[1] ; Tamsin,Woodbridge ^[2] ; Tom,Hilliard ^[3] ; Jon,Standing ^[4] ; Mary,Lewis ^[5] ; Lesley,Ward ^[6] ; Adam,Finn ^[7] ; Marion,Roderick ^[8]

作者单位： Department of Paediatric Immunology and Infectious Diseases, Bristol Royal Hospital for Children, Bristol, UK. ^[1] Community Paediatrics, Southmead House, Sirona Care and Health CIC, Kingswood, South Gloucestershire, UK. ^[2] Department of Respiratory Medicine, Bristol Royal Hospital for Children, Bristol, UK. ^[3] Department of Pharmacy, Bristol Royal Hospital for Children, Bristol, UK. ^[4] Immunisation, Sirona Care and Health CIC, South Gloucestershire, UK. ^[5] William Budd Health Centre, Knowle West Health Park, Swift pcn, Bristol, UK. ^[6] Department of Paediatric Immunology and Infectious Diseases, Bristol Royal Hospital for Children, Bristol, UK.;Population Health Sciences, University of Bristol, Bristol, Bristol, UK. ^[7] Department of Paediatric Immunology and Infectious Diseases, Bristol Royal Hospital for Children, Bristol, UK rodericks1000@hotmail.com.;Population Health Sciences, University of Bristol, Bristol, Bristol, UK. ^[8]

关键词 COVID-19 adolescent health allergy and immunology child health services paediatrics